HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
第一作者:
X-F,Wen
第一单位:
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA. xfle@mdanderson.org
作者:
主题词
动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);印迹法, 蛋白质(Blotting, Western);女(雌)性(Female);人类(Humans);免疫组织化学(Immunohistochemistry);白细胞介素8(Interleukin-8);乳房肿瘤, 实验性(Mammary Neoplasms, Experimental);小鼠(Mice);小鼠, 裸(Mice, Nude);新生血管化, 病理性(Neovascularization, Pathologic);癌基因蛋白质v-akt(Oncogene Protein v-akt);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);逆转录聚合酶链反应(Reverse Transcriptase Polymerase Chain Reaction);信号传导(Signal Transduction);凝血酶敏感蛋白1(Thrombospondin 1);转染(Transfection);血管内皮生长因子A(Vascular Endothelial Growth Factor A);p38丝裂原活化蛋白激酶类(p38 Mitogen-Activated Protein Kinases)
DOI
10.1038/sj.onc.1209685
PMID
16715132
发布时间
2022-03-18
- 浏览4

Oncogene
6986-96页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文